Back to results
US 10,952,963 B2Granted
Ready to use liquid RECK formulation
AssigneeQuVa Pharma, Inc.
InventorsTravis A. Leeah, Jianping Chen
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a ready-to-use liquid formulation comprising ropivacaine, epinephrine, clonidine, and ketorolac (collectively referred to as RECK). Also disclosed herein is a process for preparing the RECK-containing liquid formulation, as well as methods for using the same.
Claims19
A ready-to-use liquid formulation comprising:
- ropivacaine hydrochloride in an amount of about 2.5 mg/mL;
- epinephrine hydrochloride in an amount of about 5 mcg/mL, based on epinephrine free base;
- clonidine hydrochloride in an amount of about 0.8 mcg/mL;
- ketorolac tromethamine in an amount of about 0.3 mg/mL;
- sodium chloride in an amount of about 8.5 mg/mL;
- sodium metabisulfite in an amount of about 2.6 mcg/mL;
- EDTA sodium in an amount of about 0.2 mg/mL;
- optionally citric acid in an amount of about 2 mg/mL;
- a sufficient amount of sterile water for injection;
- and
- a sufficient amount of a pH adjuster to obtain a pH of from about 4.6 to about 4.9.
8 more elements
A ready-to-use liquid formulation consisting of:
- ropivacaine hydrochloride in an amount of about 2.5 mg/mL;
- epinephrine hydrochloride in an amount of about 5 mcg/mL, based on epinephrine free base;
- clonidine hydrochloride in an amount of about 0.8 mcg/mL;
- ketorolac tromethamine in an amount of about 0.3 mg/mL;
- sodium chloride in an amount of about 8.5 mg/mL;
- sodium metabisulfite in an amount of about 2 mcg/mL to about 10 mcg/mL;
- EDTA sodium in an amount of about 0.2 mg/mL;
- optionally citric acid in an amount of about 2 mg/mL;
- a sufficient amount of sterile water for injection;
- and
- a sufficient amount of a pH adjuster to obtain a pH of from about 4.6 to about 4.9.
8 more elements
Dependencies are inferred from the claim text.